• 제목/요약/키워드: CMVD

검색결과 3건 처리시간 0.018초

Identification of the Marker Genes Related With Chronic Mitral Valve Disease in Dogs

  • Yoon, Byung-Gook;Lee, Dong-Soo;Seo, Kyoung-Won;Song, Kun-Ho
    • 한국임상수의학회지
    • /
    • 제36권4호
    • /
    • pp.190-195
    • /
    • 2019
  • We aimed to identify genomic variations as well as the marker genes related with chronic mitral valve disease (CMVD) in Canis lupus familiaris using whole genome resequencing, which provides valuable resources for further study. Two ten-year old female Canis lupus familiaris English cocker spaniels were used for this study, one control and one who had been diagnosed as CMVD. For the whole genome resequencing, muscles from the left ventricular wall were collected from each dog. With the HiSeq DNA Shotgun library and $HiSeq^{TM}$ 2000 platform, whole genome resequencing was performed. From the results, we identified 5 million and 6 million variants in gene expression in the control and CMVD-diagnosed subject, respectively. We then selected the top 1,000 genes from the SNP, INS, and DEL mutation and 675 genes among them were overlapped for every mutation between the control and CMVD-diagnosed patient. Interestingly, in both groups, the intron variant (91.16 and 91.18%) and upstream variant (3.10 and 3.08%) are most highly related. Among the overlapped 675 genes, gene ontology for intracellular signal transduction is highly counted in INS, and DEL, and SNPs (35, 33, 31, respectively). In this study, we found that the COL and CDH gene families could be key molecules in identifying the difference in gene expression between control and CMVD-diagnosed dogs. We believe further studies will prove the importance of variants in key molecule expression and that these data will serve as a valuable foundation stone the study of canine CMVD.

만성 이첨판 폐쇄부전증 개에서 인슐린 분비기능 감소 (Decreased Insulin Secretion in Dogs with Chronic Mitral Valve Insufficiency)

  • 강종일;박성준;이승곤
    • 한국임상수의학회지
    • /
    • 제31권3호
    • /
    • pp.163-169
    • /
    • 2014
  • 최근 사람연구에서는 심부전과 관련하여 발생하는 인슐린 저항성이나 공복혈당 이상과 같은 혈당 대사 이상 중요한 예후인자로 받아들여지고 있다. 그러나 심부전이 있는 개에서 이와 관련된 연구는 매우 드물다. 따라서 본 연구는 혈당대사이상이 이첨판 폐쇄 부전증이 있는 개에서도 나타날 것이라고 가정하였다. 총 113마리의 보호자가 있는 개를 대상으로 혈중 insulin, glucagon, fructosamine, glucose 를 측정하였으며, 인슐린 저항성은 homeostatic model assessment (HOMA) score를 이용하였다. 실험결과 혈중 인슐린 농도는 심장병이 심해짐에 따라서 유의성 있게 감소함을 확인하였다. 반면, fructosamine, HOMA score, and 공복 혈당은 심부전의 심각도와 어떠한 상관성도 보이지 않았다. 인슐린 농도, fructosamine, HOMA 의 경우 body condition scores (BCS)와 양의 유의적 상관관계를 보였으나, 혈당의 경우 그러지 않았다. 심부전과 BCS와의 음의 유의적 상관관계 또한 확인 되었다. 본 연구를 바탕으로 자연적으로 발생한 이첨판 폐쇄부전증에 따른 심부전 환자에서 심장 병이 심해짐에 따라서 인슐린 분비 기능이 감소함을 확인하였다.

Evaluation of ST2 and NT-proBNP as Cardiac Biomarkers in Dogs With Chronic Mitral Valve Disease

  • Kim, Jung-Kook;Park, Jun-Seok;Seo, Kyoung-Won;Song, Kun-Ho
    • 한국임상수의학회지
    • /
    • 제35권2호
    • /
    • pp.35-38
    • /
    • 2018
  • Recently assessment of suppression of tumorigenicity 2 (ST2) level has become a useful cardiac biomarker in human medicine. This study compared serum ST2 levels and N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels between healthy dogs and dogs with chronic mitral valve disease. Twenty client-owned dogs were investigated. Dogs were divided into normal, asymptomatic, and symptomatic groups. Serum samples were used to measure levels of NT-proBNP and ST2. Samples for NT-proBNP were sent to IDEXX laboratory for analysis while ST2 levels were measured by using a canine interleukin 33 receptor ELISA kit. There was a significant difference in NT-proBNP levels between asymptomatic and symptomatic groups (P < 0.01), and between normal and symptomatic groups (P < 0.01). In contrast, ST2 levels were not relatively different between asymptomatic and symptomatic groups (P > 0.05). There was no significant difference was observed among all groups in ST2 study. The usefulness of measuring NT-proBNP level as a cardiac biomarker in dogs with chronic mitral valve disease was confirmed, but usefulness of the ST2 level was not observed. Further investigations are needed to evaluate the potential usefulness of ST2 level as a cardiac biomarker in canines.